OraSure Technologies Inc
$ 3.08
10.00%
26 Feb - close price
- Market Cap 204,784,000 USD
- Current Price $ 3.08
- High / Low $ 3.14 / 2.51
- Stock P/E N/A
- Book Value 5.01
- EPS -0.81
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -0.15 %
- 52 Week High 4.22
- 52 Week Low 2.08
About
OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and sample collection devices in the United States, Europe, and internationally. The company is headquartered in Bethlehem, Pennsylvania.
Analyst Target Price
$4.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-03 | 2023-05-10 |
| Reported EPS | -0.19 | -0.13 | -0.26 | -0.18 | -0.06 | -0.06 | -0.01 | -0.05 | 0.27 | 0.15 | 0.09 | 0.37 |
| Estimated EPS | -0.19 | -0.19 | -0.17 | -0.1223 | -0.0107 | -0.08 | -0.03 | 0.01 | 0.09 | 0.04 | -0.08 | 0.14 |
| Surprise | 0 | 0.06 | -0.09 | -0.0577 | -0.0493 | 0.02 | 0.02 | -0.06 | 0.18 | 0.11 | 0.17 | 0.23 |
| Surprise Percentage | 0% | 31.5789% | -52.9412% | -47.1791% | -460.7477% | 25% | 66.6667% | -600% | 200% | 275% | 212.5% | 164.2857% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OSUR
2026-02-26 23:52:34
OraSure Technologies (OSUR) reported a worsening loss in Q4 FY 2025, with a basic EPS loss of US$0.27 and revenue of US$26.8 million, raising concerns about margin recovery. The company's trailing twelve-month revenue has shrunk, and losses have deepened, leading to skepticism despite a seemingly low P/S ratio compared to the industry. The article highlights the ongoing debate between bullish investors, who see value in the low P/S, and bearish investors, who focus on the persistent unprofitability and shrinking revenue.
2026-02-26 21:52:34
OraSure Technologies reported fourth-quarter 2025 net revenue of $26.8 million, noting a 29% year-over-year decrease and a total 38% decline for 2025 due to reduced COVID-19 and other testing. Despite these challenges, management expects a return to growth in 2026, supported by improved funding, stronger gross margins, a solid balance sheet, a share repurchase program, and upcoming U.S. product launches. An analyst rating for OSUR stock is currently a Hold with a $3.00 price target.
2026-02-26 01:52:34
OraSure Technologies reported a net loss of $19.3 million, or 27 cents per share, for the fourth quarter, with an adjusted loss of 19 cents per share. The company generated $26.8 million in revenue for the quarter and a total loss of $68.7 million, or 94 cents per share, with $115 million in annual revenue. For the first quarter, OraSure anticipates revenue between $26 million and $29 million.
2026-02-26 01:52:34
OraSure Technologies, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported total net revenues of $26.8 million for Q4 2025, a 29% decrease year-over-year, and a net loss of $19.3 million. Despite a challenging funding environment in 2025, OraSure is optimistic about returning to growth in 2026 with anticipated U.S. regulatory clearances for new rapid molecular self-tests and collection devices, and continues to execute its share repurchase program.
2026-02-25 20:52:04
OraSure Technologies, Inc. (NASDAQ: OSUR) reported its financial results for the fourth quarter and full year 2025, with Q4 revenue of $26.8 million, consistent with expectations. The company anticipates a return to growth in 2026, driven by regulatory clearances and launches of new rapid molecular diagnostic tests for STIs and at-home urine collection devices. OraSure also highlighted progress on its innovation roadmap, a strong balance sheet enabling strategic investments, and ongoing share repurchases.
2026-02-25 20:52:04
OraSure Technologies, Inc. (NASDAQ: OSUR) announced its financial results for the fourth quarter of 2025, reporting total net revenues of $26.8 million, a 29% decrease from the previous year. Despite a challenging funding environment in 2025, the company's results were consistent with expectations, and they anticipate a return to growth in 2026 driven by planned regulatory clearances and product launches. OraSure remains confident in its strategy to expand access to diagnostics and continues to execute its $40 million share repurchase program.
